



1. CPMS

The Clinical Patient Management System (CPMS) is a web-based clinical user program which was developed by a sub contractor of the Commission, aiming to support the ERNs on rare, low prevalence and complex diseases. The CPMS platform is managed by the Commission and facilitates a secure electronic system, which shall help healthcare professionals of the ERN member hospitals to collaborate in the cross-border patients file assessments. This web-based will be the platform where HCP from the ERNs can assess and discuss their patients cases.

The CPMS-Platform was released by the Commission on Monday, November 20th at 12 CET. At a later stage, the CPMS will become available for healthcare providers outside ERNs to consult the highly specialised experts within ERNs. To get a better overview on the CPMS, please click on the links below, which contain a short video on CPMS, login requirements and a short info on how to get started.

If you are a healthcare professional, please click on the link and file below to request authorization and access the CPMS platform:

<https://cpms.ern-net.eu/login/>

<https://cloud.ern-lung.eu/index.php/s/eIKcNhgCHCX873w>

To get a quick overview, please click the link below to view this short video:

<https://webgate.ec.europa.eu/ern/imgs/cpms%20overview.mp4>



2. Conflict of Interest Policy

As you know the mission of ERN-LUNG is providing excellence and improvement in treatment for the patients suffering on rare and complex diseases of the respiratory system. As a non-profit, international, professional, patient-centric, and scientific network, the independence and integrity of ERN LUNG is an important prerequisite of the project. All ERN-LUNG members, therefore, are obliged to follow a Conflict of Interest Policy to ensure there is no commercial/private interest involved. By the way, the development and the compliance of a Conflict of Interest Policy is one of the deliverables we need to provide to the EU.

There is already an ongoing discussion in the ERN Coordinators' Working Group about the implementation of such a Policy; the draft version however is still in a very complex shape that might not be the solution to go with. As we have to start now, we took the template created by ERS, adapted to our needs.

The main goal is not to prohibit or hinder your interaction (also financial interaction) with industry but rather to achieve transparency. The Medical Steering Committee will receive the information and will report to the Board of ERN-LUNG.

3. Advisory Board Meeting

The first Advisory Board Meeting took place on November 15, 2017, which was called in via conference call. The meeting was attended by a wide range of experts from several Member States. The objective of this first meeting was one the one hand, to discuss the possible tasks, the key areas of work, and to create a shared understanding of ERN-LUNG and requirements associated to move forward and for the fulfillment of project goals. On the other hand, to get to know each other and to find out in what kind of activities they would like to get involved in.



ERN - LUNG Newsletter



**European
Reference
Network**

for rare or low prevalence
complex diseases

 **Network**
Respiratory Diseases
(ERN-LUNG)

Responsible for the content of this newsletter:

Coordinator of ERN-LUNG
Prof. Dr. T.O.F. Wagner
University Hospital Frankfurt / Germany

Email: t.wagner@em.uni-frankfurt.de
Issue published on: August 30, 2017

